US Reclassifies Certain Marijuana Products as Lower-Risk Substance

The United States government has moved to reclassify certain marijuana products under a less restrictive drug category, marking one of the most consequential federal drug policy shifts in decades. The reclassification affects specific cannabis-derived products and adjusts their regulatory standing under federal controlled substances law.

The decision reflects years of mounting scientific evidence, shifting public opinion, and pressure from medical communities arguing that cannabis-based treatments have been unfairly categorised alongside high-risk narcotics. The reclassification does not amount to full federal legalisation but significantly alters the legal and regulatory landscape for medical and commercial cannabis activities.

The move is expected to affect research access, taxation, and banking services for cannabis businesses, which have long faced restrictions tied to the substance's prior classification. Medical professionals broadly welcomed the change as an overdue recognition of clinical applications for certain cannabis compounds.

The reclassification is likely to reopen legislative debates across multiple US states and internationally, where policymakers track American federal drug policy as a reference point for their own regulatory frameworks.